January 19, 2021 -- Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody therapeutics.
Under the deal, Twist Biopharma will collaborate with Serotiny to discover novel chimeric antigen receptors (CAR) for CAR T-cell therapies. The firm will provide Serotiny with custom DNA libraries that encode CARs. Serotiny will then engineer and characterize unique CARs on a large scale to screen for receptor designs that offer improved therapeutic properties and applicability to a wide range of solid tumors, according to the company. Twist will be able to license any technology resulting from the collaboration.
In its partnership with Applied StemCell, Twist will add the firm's Targatt Chinese hamster ovary (CHO) cell lines for screening, selecting, and characterizing any antibodies discovered for its partnered and internal programs.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
